PD04.03. SMYD2 as a Novel Molecular Regulator of Immune Evasion and Immunosuppression in Esophagogastric Junction Cancer

Clicks: 4
ID: 325717
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #114 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Molecular Biology/Pathology Background Immune checkpoint inhibitors targeting PD-1/PD-L1 have caused a paradigm shift in esophageal and gastric cancer treatment; however, oncogenic mechanisms regulating immune evasion and Treg-mediated immunosuppression remain unclear. We investigated the role of SMYD2 in tumor immunity. Methods SCC, EAC, and GC cell lines and clinical specimens from 101 patients with esophagogastric junction adenocarcinoma who underwent curative resection were analyzed. Immunohistochemical evaluation of SMYD2 expression was performed in clinical samples. Functional analyses included siRNA-mediated SMYD2 knockdown, cell proliferation, migration, and invasion assays, and assessment of PD-L1 protein expression. Co-culture experiments with activated T cells were conducted to evaluate T-cell–mediated antitumor activity. Ongoing analyses assess correlations among SMYD2 expression, PD-L1 expression, immune checkpoint inhibitor responsiveness, and Treg-related immunosuppressive mechanisms. Results High SMYD2 expression was significantly associated with poor prognosis and was identified as an independent prognostic factor (HR 3.69, P < 0.01). SMYD2 knockdown in EAC cell lines induced cell cycle arrest with significant growth inhibition and reduced migration (P < 0.01). In SCC, EAC, and GC cell lines, SMYD2 knockdown significantly decreased PD-L1 protein expression (P < 0.01). Co-culture with activated T cells demonstrated enhanced T-cell–mediated cytotoxicity against SMYD2-knockdown cells compared with controls. Conclusion SMYD2 may regulate novel mechanisms of immune evasion and immunosuppression in esophageal cancer and could serve as both a predictive biomarker for immunotherapy sensitivity and a therapeutic target to overcome tumor immune escape.
Reference Key
openalex_W7203874206 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Satoshi Hamada, Shuhei Komatsu, Taisuke Imamura, Takuma Ohashi, Keiji Nishibeppu, Jun Kiuchi, Hirotaka Konishi, Hitoshi Fujiwara, Hitoshi Tsuda, Atsushi Shiozaki
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.098
URL
https://doi.org/10.1093/dote/doag077.098
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.